Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ...

The company maintains a cash runway into the fourth quarter of 2025 and continues its focus on advancing its norovirus and other vaccine programs. Vaxart’s strategic efforts include exploring ...